Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | NEK4 | P51957 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.39 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712814 | 0.91 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL1713158 | 0.88 | ADORA2A (0.48) | PIM1GSK3ADYRK1APIM3ADORA3 | |
| SCHEMBL1713144 | 0.86 | ADORA2B (0.36) | ADORA3ADORA2AADORA2B | |
| SCHEMBL1713020 | 0.85 | ADORA2A (0.47) | ADORA3ADORA2AADORA2B | |
| SCHEMBL1713177 | 0.84 | ADORA2B (0.49) | ADORA3ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL1713057 | 0.80 | ADORA2B (0.40) | ADORA3ADORA2AADORA2B | |
| SCHEMBL2077334 | 0.79 | ADORA2B (0.44) | ADORA3ADORA2AADORA2B | |
| SCHEMBL1713173 | 0.76 | ADORA2A (0.46) | ADORA3ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL1712833 | 0.76 | ADORA2A (0.40) | ADORA3ADORA2AADORA2B | |
| SCHEMBL1713342 | 0.76 | ADORA2B (0.37) | ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | claimed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | claimed |
| US-7863285-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| EP-2049544-B1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2010-11-03 | — | — | EP | claimed |
| EP-2049544-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | Incyte Corporation (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090088446-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-04-02 | — | — | US | claimed |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-03-19 | — | — | US | claimed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | claimed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2049544-B9 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORP (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902205-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7462624-B2 | Purinone derivatives as HM74a agonists | INCYTE CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150026-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088446-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | CDC7 2915/4885ROCK2 4323/4885MAP4K4 1453/4885 |
| US-20090076269-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | CDC7 2915/4885ROCK2 4323/4885MAP4K4 1453/4885 |
| US-20080045555-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | CDC7 2915/4885ROCK2 4323/4885MAP4K4 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.